A significant circadian variation has been shown to characterize cholesterol and triglycerides, with predictably highest values at the end of the diurnal active hours, and lowest values after awakening [Am Heart J. 2000;139:164-173]. It has thus been suggested that statins should be administered at night. However, most studies on the efficacy of statins have not evaluated a potential change in effects as a function of the circadian time of dosing. Accordingly, we evaluated the potential administration time-dependent changes in the lipid profile of hyperlipidemichypertensive patients treated with statins. We studied 2486 patients (1167 men), 59.7Ϯ13.8 years of age, with grade 1-2 essential hypertension and dyslipemia, all under treatment with statins. We evaluated the circadian time of statin administration (awakening-breakfast, lunch, bedtime-dinner, other) and its potential correlation with lipid control, according to NCEP-III criteria (LDL-cholesterol Ͻ 160, Ͻ130, or Ͻ100 mg/dL, according to cardiovascular risk stratification). Therapeutic compliance was evaluated using the Morisky-Greeen test. Atorvastatin was the statin most frequently used (41.3%), followed by simvastatin (28.0%) and pravastatin (17.4%). Most of the patients were taken their statin at night (67.3%), although 25.4 were taken statins with lunch, and a low 4.1% were taken statins in a single morning dose. With respect to lipid control, 36.3% of the patients taken statins at night were controlled. This percentage was significantly reduced to 20% in patients taken statins with lunch (PϽ0.001). Therapeutic compliance was also significantly higher when statins were taken at bedtime (87.7%) as compared to midday (78.6%, PϽ0.001). As a clear example of chronotherapy, in hyperlipidemic patients with essential hypertension the time of treatment with statins should always be recommended to be bedtime, in keeping with the expected high values of lipids at the end of the diurnal active period, the significantly increased efficacy after bedtime dosing with all statins here evaluated, and a higher patient compliance at bedtime as compared to the administration of statins either with lunch or at the highly less efficient awakening time. To investigate whether the treatment with simvastatin 20 mg/die may change polymorphonuclear leukocyte (PMN) function in high-risk patients, the chemotactic index (CI, i.e. stimulated chemotaxis/spontaneous migration) and reactive oxygen species (ROS) production were studied in isolated PMNs obtained from patients before institution of statin treatment (1D-e) and thereafter, at 3 days (3D-e) and at 30 days of treatment (30D-e). Functional responses were obtained by stimulation of the cells with fMLP, a chemotactic peptide acting on membrane receptors, and PMA, a direct activator of protein kinase C.
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Eight high-risk subjects (mean age 61Ϯ8 years; 5 patients with type-2 diabetes in diet treatment, 3 dyslipidemic patients; non-smokers, no heavy sporting activities) were studied. In patients at 1D-e the mean total cholesterol (T-c) was 238Ϯ23 mg/dl, LDL-c was 165Ϯ17 mg/dl, HDL-c was 47.5Ϯ5.3 mg/dl, and triglycerides were 125Ϯ50 mg/dl. T-c, LDL-c and ApoB significantly decreased at both 3D-e (202Ϯ27 mg/dl, 134Ϯ25 mg/dl, and 108Ϯ15 mg/dl, respectively) and 30D-e (164Ϯ28 mg/dl, 96Ϯ21 mg/dl, and 70Ϯ32 mg/dl, respectively). Differences were always statistically significant vs 1D-e (PϽ0.05 by ANOVA followed by Student Newman Keuls post test). The dietary habits (as evaluated by a diary) and the fasting glycemia did not change during the 30-days follow-up. The CI in PMNs from patients was 1.29Ϯ0.06 at 1D-e and did not change at 3D-e and at 30D-e, while PMA-induced ROS production was significantly reduced at the 30D-e, both with respect to 1D-e and 3D-e (PϽ0.05 vs both 1D-e and 3D-e). By contrast, fMLP-induced ROS generation remained unchanged throughout the treatment.
The present results show that the treatment with simvastatin in highrisk patients is associated with a reduction of stimulated ROS production by PMNs. The effect is stimulus specific, and this finding may support an action of simvastatin on intracellular (rather than membrane receptor) targets in the modulation of the inflammatory response. Isolated Systolic Hypertension (ISH) has been shown to increase cardiovascular disease morbidity and mortality. In this study, we searched for differences in the lipid profile between subjects with ISH and those with essential hypertension.
We studied 442 [212 (48%) were men] hypertensives, who had never been treated. Their median age was 56 (range: 18 -83) years. Among them, 135 (30.5%) patients had ISH [Systolic Blood Pressure (SBD) Ͼ 140mmHg and Diastolic Blood Pressure (DBP) Ͻ 90mmHg]. All patients had a full lipid profile.
Persons with ISH were older than other hypertensives (62.0Ϯ10.8 vs 53.4Ϯ11.9 years, pϽ0.001). There was no difference in the sex distribution between the two groups [66 out of 135 (48.9%) vs 146 out of 307 (47.6%) were men, respectively]. Those with ISH had significantly greater pulse pressure (PP) (71.6Ϯ16.1 vs 60.6Ϯ16.8 mmHg, pϽ0.001) and significantly smaller body mass index (BMI) (29.3Ϯ3.9 vs 30.9Ϯ5.2, pϽ0.01), when compared with the rest hypertensives.
Subjects with ISH had significantly higher high density lipoprotein (HDL) than the rest hypertensives (51.8Ϯ17.6 vs 46.9Ϯ11.6mg/dl; pϽ0.01). There were no other significant differences in the rest lipid profile between the two groups.
In conclusion, our study suggests that among untreated patients with essential hypertension those with ISH had a more favourable lipid profile.
